Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Josep M. Jansat"'
Autor:
Josep M. Jansat, Stacy C. Dilzer, Cynthia Caracta, Stephan Ortiz, Esther Garcia Gil, Kenneth C. Lasseter
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 25:193-199
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway obstruction and increased cholinergic tone. The global initiative for chronic obstructive lung disease (GOLD) guidelines recommend long-acting anticholinergics for CO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19a7a39fcdae24bb9b8f902cdc54cf09
https://doi.org/10.1016/j.pupt.2012.02.002
https://doi.org/10.1016/j.pupt.2012.02.002
Autor:
Cynthia Caracta, Josep M. Jansat, Stephen Flach, Esther Garcia Gil, Stephan Ortiz, Fanying Li, John Ho
Publikováno v:
Biopharmaceutics & Drug Disposition. 33:39-45
Aclidinium bromide is a novel, inhaled long-acting muscarinic antagonist with low systemic activity developed for the treatment of COPD. It is an ester compound rapidly hydrolysed in plasma into inactive alcohol and acid metabolites. In this Phase I,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97a2d9588dd803e9e1e4948b460e4524
https://doi.org/10.1002/bdd.1773
https://doi.org/10.1002/bdd.1773
Publikováno v:
Clinical Therapeutics. 32:1798-1812
Aclidinium bromide is an inhaled, long-acting muscarinic antagonist currently in development for the treatment of chronic obstructive pulmonary disease. Renal impairment may affect drug clearance.This study was conducted to evaluate the pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b536eefd31d1dac2f53964de8582855
https://doi.org/10.1016/j.clinthera.2010.09.002
https://doi.org/10.1016/j.clinthera.2010.09.002
Autor:
Esther Garcia Gil, Guy Joos, Francesc Peris, Josep M. Jansat, Romain Pauwels, Vanessa Schelfhout, Pau Ferrer
Publikováno v:
British Journal of Clinical Pharmacology. 69:458-464
AIM Aclidinium bromide is a muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). This phase I trial in healthy subjects investigated the bronchodilator activity of aclidinium and its ability to reduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88829593f847252966aa339224c2d3d9
https://doi.org/10.1111/j.1365-2125.2010.03622.x
https://doi.org/10.1111/j.1365-2125.2010.03622.x
Autor:
Andreas Schrödter, Barbara Miletzki, Gonzalo de Miquel, Matthias Gurniak, Rosa Lamarca, Josep M. Jansat
Publikováno v:
The Journal of Clinical Pharmacology. 49:1239-1246
Systemic exposure to anticholinergics used for chronic obstructive pulmonary disease (COPD) may lead to side effects. This study assessed safety, tolerability, and pharmacokinetics of multiple doses of aclidinium bromide, a novel, long-acting antimus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b38f37d06ab13f190da15cc9a0189eb
https://doi.org/10.1177/0091270009336353
https://doi.org/10.1177/0091270009336353
Publikováno v:
CNS Drug Reviews. 8:217-234
Almotriptan is a new anti‐migraine agent with nanomolar affinity for human 5‐HT(1B), 5‐HT(1D), and 5‐HT(1F) receptors, weak affinity for 5‐HT(1A) and 5‐HT(7) receptors and no significant affinity for more than 20 other pharmacological rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f3f803d4d8b5bfb2307e2d9da25292a
https://doi.org/10.1111/j.1527-3458.2002.tb00226.x
https://doi.org/10.1111/j.1527-3458.2002.tb00226.x
Publikováno v:
Drug Metabolism and Disposition. 31:404-411
Almotriptan is a novel highly selective 5-hydroxytryptamine(1B/1D) agonist developed for the acute oral treatment of migraine. The in vitro metabolism of almotriptan has been investigated using human liver subcellular fractions and cDNA-expressed hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a06c83c03eba8615ba6dc24c352bded1
https://doi.org/10.1124/dmd.31.4.404
https://doi.org/10.1124/dmd.31.4.404
Publikováno v:
The Journal of Clinical Pharmacology. 42:1303-1310
Absolute bioavailability, pharmacokinetics, and urinary excretion of almotriptan, a novel 5-HT(1B/1D) receptor agonist, were studied in 18 healthy males following single intravenous (i.v.) (3 mg), subcutaneous (s.c.) (6 mg), and oral (25 mg) doses. V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5cd0023e26226b911b3645e548f05dc
https://doi.org/10.1177/0091270002042012006
https://doi.org/10.1177/0091270002042012006
Autor:
Kristi K. Ryan, David J. A. Bell, Nkechi E. Azie, Joseph C. Fleishaker, Moira T. Burke, Josep M. Jansat, Barabara J. Carel
Publikováno v:
British Journal of Clinical Pharmacology. 51:437-441
Aims To assess the effect of a reversible MAO-A inhibitor, moclobemide, on the single-dose pharmacokinetics of almotriptan and assess the clinical consequences of any interaction. Methods Twelve healthy volunteers received the following treatments in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99499d3f6fb11dcf772f06a026b32519
https://doi.org/10.1046/j.1365-2125.2001.01367.x
https://doi.org/10.1046/j.1365-2125.2001.01367.x
Autor:
Josep M. Jansat, Esther Garcia Gil, Silvia Pascual, Jutta Beier, Karin Schmid, Stephan de la Motte
Publikováno v:
International journal of clinical pharmacology and therapeutics. 50(6)
OBJECTIVE To investigate the pharmacokinetics, safety and tolerability of aclidinium bromide 200 μg and 400 μg after a single dose and repeated once-daily doses in younger and elderly patients with moderate or severe chronic obstructive pulmonary d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763e0b03526dd5a08b767729b6802bd2
https://pubmed.ncbi.nlm.nih.gov/22541745
https://pubmed.ncbi.nlm.nih.gov/22541745